Stacey Johnson
Stacey Johnson is the editor of Signals and a contributor. For 25 years, Stacey has been providing strategic communications counsel to government, corporate, technology and health organizations. She began her career at the CTV Television Network and then moved to Hill & Knowlton Canada where she advised clients in a variety of industries and sectors. Stacey is the Vice President, Communications and Marketing for CCRM, a leader in developing and commercializing regenerative medicine-based technologies and cell and gene therapies. She has a Master's degree in Public Relations. You can follow her on Twitter @msstaceyerin.
Posts by: Stacey
Right Turn: Cross my heart
. In 2012, Deborah Lieu from the University of California, Davis was granted $1.3 million by the California Institute for Regenerative Medicine (CIRM) to develop pacemaking cells from human induced pluripotent stem cells (HiPSCs) to replace electronic pacemakers. I first wrote about this in Keeping pace with stem cell technology. With Valentine’s Day just a […]
Right Turn: Blockbuster toy or super (silly) biomaterial?
. Signals’ mandate is to bring you, dear reader, blogs about stem cells, commercialization and biomaterials, but lately there hasn’t been much of the latter; therefore, I’ve decided to try to fill that gap. But before you get too excited, I am in no way an expert on biomaterials, despite my affection for them (and […]
Right Turn: Remembering the warning signs of Alzheimer’s disease
. Alzheimer’s disease is a chronic, neurodegenerative disease characterized by loss of memory and changes in behaviour in the early stage. It typically starts slowly and progresses, within a decade, to death from an external factor, such as an infection or pneumonia, or the person’s body completely shuts down. According to the Alzheimer Society of […]
Luck is on their side in “bad luck” cancer study
. Before you read my blog, I recommend that you first read Sara Nolte’s blog “Bad luck, bad science, or bad reporting?” In it, Sara does an excellent job explaining and commenting on Drs. Cristian Tomasetti’s and Bert Vogelstein’s study “Variation in cancer risk among tissues can be explained by the number of stem cell […]